A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
A Double-Blind, Randomized, Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza A
Sponsor: Vir Biotechnology, Inc.
Terminated
VIR-2482 1200 mg did not demonstrate efficacy versus placebo in the primary analysis of the primary endpoint
Other Influenza A trials with similar outcome
Listed as NCT05567783, this PHASE2 trial focuses on Influenza A and remains terminated or withdrawn. Sponsored by Vir Biotechnology, Inc., it has been updated 7 times since 2022, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
7 versions recorded-
Oct 2024 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Oct 2024 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Oct 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Active Not Recruiting → Terminated
-
Jan 2023 — Oct 2023 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
▶ Show 2 earlier versions
-
Dec 2022 — Jan 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Oct 2022
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Vir Biotechnology, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .